Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.
- Conditions
- Psicosi associata al morbo di ParkinsonMedDRA version: 9.1Level: LLTClassification code 10013113Term: Disease Parkinson's
- Registration Number
- EUCTR2007-000307-15-IT
- Lead Sponsor
- OVATION PHARMACEUTICALS INC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective is to assess the safety and efficacy of 20, 40, and 60 mg per day of melperone syrup (5 mg/ml) in subjects with psychosis associated to Parkinson’s Disease. <br>;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method